Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Risk of recurrent H pylori infection after initial eradication

This  week's issue of the Journal of the American Medical Association investigates the risk of recurrent H pylori infection 1 year after initial eradication therapy in Latin American communities.

News image

The long-term effectiveness of Helicobacter pylori eradication programs for preventing gastric cancer will depend on recurrence risk and individual and community factors.

Dr Douglas Morgan and colleagues estimated the risk of H pylori recurrence and assess factors associated with successful eradication 1 year after treatment.

Cohort analysis of 1463 randomized trial participants aged 21 to 65 years from 7 Latin American communities, who were treated for H pylori and observed between 2009 and 2011.

Patients were randomized to 1 of 3 treatment groups, including 14-day lansoprazole, amoxicillin, and clarithromycin, 5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole, or 5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole.

The research team reported that participants with a positive C-urea breath test (UBT) 6 to 8 weeks posttreatment were offered voluntary re-treatment with 14-day bismuth-based quadruple therapy.

One year after treatment for H pylori infection, recurrence occurred in 12%
Journal of the American Medical Association

Recurrent infection after a negative posttreatment urea breath test and factors associated with successful eradication at 1-year follow-up.

The doctors noted that among participants with urea breath test-negative results who had a 1-year follow-up urea breath test, 125 tested urea breath test positive, a recurrence risk of 12%.

Recurrence was significantly associated with study site, nonadherence to initial therapy, and children in the household.

The researchers found that of the 281 with positive posttreatment urea breath test results, 138 completed re-treatment, of whom 93 tested urea breath test negative at 1 year.

Among the 1340 who had a 1-year urea breath test, 80%, 79%, and 78% had urea breath test-negative results in the triple, sequential, and concomitant groups, respectively, with 79% overall effectiveness.

In a single-treatment course analysis that ignored the effects of re-treatment, the percentage of urea breath test-negative results at 1 year was and was significantly associated with study site, adherence to initial therapy, male sex, and age.

The team of doctors reported that one-year effectiveness among all 1463 enrolled participants, considering all missing urea breath test results as positive, was 73%.

Dr Morgan's team concluded, "One year after treatment for H pylori infection, recurrence occurred in 12% of participants who had negative posttreatment urea breath test results."

"Recurrence determinants may be as important as specific antibiotic regimen in determining the long-term success of H pylori eradication interventions."

"Study findings are relevant to the feasibility of programs for the primary prevention of gastric cancer in high-incidence regions of Latin America."

JAMA 2013; 309(6): 578-586
15 February 2013

Go to top of page Email this page Email this page to a colleague

 29 March 2015

Advanced search
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease
 27 March 2015 
Sexual functioning in IBD
 26 March 2015 
Antimicrobial therapy in cirrhosis with spontaneous bacterial peritonitis
 26 March 2015 
Metformin as a chemopreventive agent for Barrett's
 26 March 2015 
Survival of untreated hepatocellular carcinoma
 25 March 2015 
Genetics and Crohn's disease
 25 March 2015 
Mortality in Barrett’s–related T1 esophageal adenocarcinoma
 25 March 2015 
Cytomegalovirus and IBD
 24 March 2015 
Prevention of colorectal cancer after screening
 24 March 2015 
Functional GI disorders and body mass index
 24 March 2015 
Quality of life in children with fecal incontinence
 23 March 2015 
Fibrosis in NAFLD vs NASH
 23 March 2015 
The unmasking of Whipple's disease
 23 March 2015 
Predicting the quality of colon cancer care
 20 March 2015 
Interventions for eosinophilic esophagitis
 20 March 2015 
Colorectal cancer risk and genetic variants
 20 March 2015 
Screening for Barrett's esophagus
 19 March 2015 
Hypnotherapy for IBS
 19 March 2015 
Poor mental and physical health in HCV
 19 March 2015 
Dedicated care for diverticular disease
 18 March 2015 
Practice guidelines for colorectal polyps
 18 March 2015 
Out-of-hours endoscopy for upper GI bleeding
 18 March 2015 
H. pylori eradication and lipids
 17 March 2015 
H. pylori test-and-treat program and gastric cancer
 17 March 2015 
Adalimumab in Crohn’s disease
 17 March 2015 

Low-dose PPIs and GI bleeding in patients receiving aspirin

 16 March 2015 
Microscopic colitis
 16 March 2015 
Cholestasis of pregnancy with HCV
 16 March 2015 
Hybrid therapy for H. pylori
 13 March 2015 
Medicare patients and payments to gastroenterologists
 13 March 2015 
Appendectomy in ulcerative colitis
 13 March 2015 

Racial disparities in gluten-sensitive problems

 12 March 2015 
Predicting IBD in IBS patients
 12 March 2015 
Patient knowledge of IBS
 12 March 2015 
Nonceliac gluten sensitivity
 11 March 2015 

Prediction of malignant bile duct obstruction

 11 March 2015 
NAFLD–related hepatocellular carcinoma
 11 March 2015 
Assessment of eosinophilic esophagitis
 10 March 2015 
Poor disease course in pediatric ulcerative colitis
 10 March 2015 
Risk for gastroesophageal reflux symptoms
 10 March 2015 
Outcomes in Crohn's therapy
 09 March 2015 
Fibre usage in ulcerative colitis in remission
 09 March 2015 
Risk of C. difficile upon hospital admission
 09 March 2015 
Gastric Cancer detection during GI endosocopy
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 04 March 2015 
Progression of Barrett's
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
Risk of anastomotic leak after colectomy
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us